Mereo Posts Early Upbeat Look At Brittle Bone Data For Setrusumab
Executive Summary
The open-label Phase IIb data link setrusumab, licensed from Novartis, to improvements in bone density, offering encouragement for Mereo ahead of a critical upcoming readout for its lead program.